KMT2B and hepatocellular carcinoma: Our previous study revealed that KMT2B was recurrently targeted by HBV DNA > 100 times in patients with hepatocellular carcinoma (Li et al., 2020), suggesting that KMT2B is a novel and critical regulator of hepatocellular carcinoma proliferation and metastasis (data not shown).